scholarly journals Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses

Cancer ◽  
2003 ◽  
Vol 98 (11) ◽  
pp. 2410-2419 ◽  
Author(s):  
Hillary H. Wu ◽  
Moshe Talpaz ◽  
Richard E. Champlin ◽  
Susan R. Pilat ◽  
Razelle Kurzrock
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Failure ◽  
Colony Stimulating Factor ◽  
Long Term Follow Up ◽  
Factor Therapy ◽  
Macrophage Colony Stimulating Factor ◽  
Macrophage Colony ◽  
Stimulating Factor

scholarly journals Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony- stimulating factor

Blood ◽  
1993 ◽  
Vol 82 (5) ◽  
pp. 1422-1427
Author(s):  
J Nemunaitis ◽  
K Shannon-Dorcy ◽  
FR Appelbaum ◽  
J Meyers ◽  
A Owens ◽  
...  
Keyword(s):  
Fungal Infection ◽  
Adjunctive Therapy ◽  
Human Macrophage ◽  
Colony Stimulating Factor ◽  
Long Term Follow Up ◽  
Macrophage Colony Stimulating Factor ◽  
Macrophage Colony ◽  
Stimulating Factor

Mortality of bone marrow transplant (BMT) patients who develop invasive fungal infection is greater than 80%. Long-term follow-up of 46 consecutive BMT patients who received recombinant human macrophage colony-stimulating factor (rhM-CSF) as adjunctive therapy with standard antifungal treatment who were entered into phase I/II trials at The Fred Hutchinson Cancer Research Center is reported. rhM-CSF (100 micrograms/m2 to 2,000 micrograms/m2; Chiron/Cetus Corporation, Emeryville, CA) was administered from day 0 to 28 after determination of progressive fungal disease. Results of long-term follow-up of fungal infection, relapse, and survival were compared with 58 similar historical controls. Multivariable analysis of the patients who received rhM-CSF showed two factors that significantly correlated with poor survival: Karnofsky score < or = 20% and Aspergillus infection. Overall, survival of patients who received rhM-CSF was greater than that of historical patients (27% v 5%) and was entirely because of a 50% survival rate in patients with Candida infection and Karnofsky scores greater than 20%. Prospective, randomized, controlled trials to determine efficiency of rhM-CSF are indicated and should be directed at patients with invasive candidiasis.

scholarly journals Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony- stimulating factor

Blood ◽  
1993 ◽  
Vol 82 (5) ◽  
pp. 1422-1427 ◽  
Author(s):  
J Nemunaitis ◽  
K Shannon-Dorcy ◽  
FR Appelbaum ◽  
J Meyers ◽  
A Owens ◽  
...  
Keyword(s):  
Fungal Infection ◽  
Adjunctive Therapy ◽  
Human Macrophage ◽  
Colony Stimulating Factor ◽  
Long Term Follow Up ◽  
Macrophage Colony Stimulating Factor ◽  
Macrophage Colony ◽  
Stimulating Factor

Abstract Mortality of bone marrow transplant (BMT) patients who develop invasive fungal infection is greater than 80%. Long-term follow-up of 46 consecutive BMT patients who received recombinant human macrophage colony-stimulating factor (rhM-CSF) as adjunctive therapy with standard antifungal treatment who were entered into phase I/II trials at The Fred Hutchinson Cancer Research Center is reported. rhM-CSF (100 micrograms/m2 to 2,000 micrograms/m2; Chiron/Cetus Corporation, Emeryville, CA) was administered from day 0 to 28 after determination of progressive fungal disease. Results of long-term follow-up of fungal infection, relapse, and survival were compared with 58 similar historical controls. Multivariable analysis of the patients who received rhM-CSF showed two factors that significantly correlated with poor survival: Karnofsky score < or = 20% and Aspergillus infection. Overall, survival of patients who received rhM-CSF was greater than that of historical patients (27% v 5%) and was entirely because of a 50% survival rate in patients with Candida infection and Karnofsky scores greater than 20%. Prospective, randomized, controlled trials to determine efficiency of rhM-CSF are indicated and should be directed at patients with invasive candidiasis.

Use of granulocyte-macrophage colony-stimulating factor in patients with malignancy and bone marrow failure

1990 ◽  
Vol 8 (S1) ◽  
pp. 303-313 ◽  
Author(s):  
Richard K. Shadduck ◽  
Craig S. Rosenfeld ◽  
Matthew Sulecki ◽  
Nabil Phillips ◽  
Donna Przepiorka ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Failure ◽  
Colony Stimulating Factor ◽  
Macrophage Colony Stimulating Factor ◽  
Macrophage Colony ◽  
Stimulating Factor
Sign in / Sign up

Export Citation Format

Share Document